Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 9:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 241 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Abdominal Neoplasm Clear all
Recruiting Phase 1Phase 2 Interventional

A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors

NCT05592626
View directory record Official record
Conditions
Advanced Solid Tumors, Genital Neoplasm, Female, Urogenital Neoplasms, Lung Neoplasm, Neoplasms by Site, Papillomavirus Infection, Epstein-Barr Virus Infections, Carcinoma, Neoplasms, Vulvar Neoplasms, Vulvar Diseases, Abdominal Neoplasm, NSCLC (Non-small Cell Lung Cancer), Colorectal Cancer
Interventions
STAR0602, Irinotecan (Camptosar), Docetaxel (Taxotere)
Drug · Combination Product
Lead sponsor
Marengo Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
366 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
13
States / cities
Sacramento, California • Celebration, Florida • Miami, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 19, 2026, 9:15 PM EDT
Completed Not applicable Interventional

Mindful Movement and Breathing to Improve Outcomes of Gynecologic Surgery

NCT01593657
View directory record Official record
Conditions
Gynecologic Malignancy, Abdominal Surgery by Laparotomy, Pain, Psychological Distress, Lung Function, Surgical Complications
Interventions
Mindful Movement and Breathing program, Questionnaire administration, The Observer Mobility Scale, Volumetric Incentive Spirometry
Other · Procedure
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 3, 2018 · Synced Oct 19, 2026, 9:15 PM EDT
Completed Phase 1 Interventional Results available

Talimogene Laherparepvec for the Treatment of Peritoneal Surface Malignancies

NCT03663712
View directory record Official record
Conditions
Peritoneal Surface Malignancy
Interventions
Talimogene Laherparepvec
Biological
Lead sponsor
Dan Blazer III, M.D.
Other
Eligibility
18 Years to 99 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
3
States / cities
Chicago, Illinois • Durham, North Carolina • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 20, 2024 · Synced Oct 19, 2026, 9:15 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Quality of Life Study for Pediatric and Adult Patients Undergoing Hyperthermic Peritoneal Perfusion With Cisplatin

NCT00502177
View directory record Official record
Conditions
Peritoneal Neoplasms
Interventions
Questionnaire
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
1 Year to 18 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 24, 2018 · Synced Oct 19, 2026, 9:15 PM EDT
Active, not recruiting Phase 4 Interventional

Registry of Sarcoma Patients Treated With Permanently Implantable LDR CivaSheet®

NCT04033081
View directory record Official record
Conditions
Sarcoma
Interventions
CivaSheet
Device
Lead sponsor
CivaTech Oncology
Industry
Eligibility
Not listed
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Oct 19, 2026, 9:15 PM EDT
Completed Phase 1 Interventional

Pilot Study of Epoetin Alfa for Patients Having Abdominal or Pelvic Surgery for Cancer

NCT00294203
View directory record Official record
Conditions
Anemia
Interventions
Epoetin Alfa group, Placebo group
Drug · Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
2
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 15, 2014 · Synced Oct 19, 2026, 9:15 PM EDT
Recruiting Phase 1 Interventional

Study of Preoperative Radiation Therapy in Participants With Resectable Recurrent Abdominal Adrenocortical Carcinoma

NCT06487481
View directory record Official record
Conditions
Adrenocortical Carcinoma (ACC), Recurrent Adrenocortical Carcinoma (ACC), Recurrent Abdominal Adrenocortical Carcinoma (ACC), Carcinoma, Adrenocortical, Carcinoma, Adrenal Cortical
Interventions
Surgical resection, Preoperative RT
Procedure · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2040
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 19, 2026, 9:15 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Topotecan and Gefitinib (Iressa) for Ovarian, Peritoneal, or Fallopian Tube Cancer

NCT00317772
View directory record Official record
Conditions
Ovarian Cancer, Peritoneal Neoplasms, Fallopian Tube Cancer
Interventions
Topotecan, Gefitinib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Female only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 7, 2022 · Synced Oct 19, 2026, 9:15 PM EDT
Terminated Phase 2 Interventional

A Phase 2, Single-Arm Study of Volociximab Monotherapy in Subjects With Platinum-Resistant Advanced Epithelial Ovarian Cancer or Primary Peritoneal Cancer

NCT00516841
View directory record Official record
Conditions
Ovarian Cancer, Peritoneal Neoplasms
Interventions
Volociximab
Drug
Lead sponsor
Facet Biotech
Industry
Eligibility
18 Years and older · Female only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
19
States / cities
Los Angeles, California • Orange, California • San Diego, California + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2012 · Synced Oct 19, 2026, 9:15 PM EDT
Active, not recruiting Not applicable Interventional

Acupuncture for the Management of Postoperative Pain in Patients With Pancreatic or Colorectal Cancer Undergoing Surgery

NCT04560712
View directory record Official record
Conditions
Resectable Colorectal Carcinoma, Resectable Digestive System Carcinoma, Resectable Pancreatic Carcinoma
Interventions
Acupuncture Therapy, Best Practice, Questionnaire Administration
Procedure · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 19, 2026, 9:15 PM EDT
Terminated Phase 2 Interventional Results available

Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer

NCT00903396
View directory record Official record
Conditions
Anal Cancer, Carcinoma of the Appendix, Colorectal Cancer, Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Gastric Cancer, Gastrointestinal Carcinoid Tumor, Liver Cancer, Nausea and Vomiting, Pancreatic Cancer, Primary Peritoneal Cavity Cancer, Small Intestine Cancer
Interventions
palonosetron hydrochloride, placebo
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
69
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Moline, Illinois + 37 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2017 · Synced Oct 19, 2026, 9:15 PM EDT
Recruiting Phase 1 Interventional

Intraperitoneal Paclitaxel With NALIRIFOX for Pancreatic Ductal Adenocarcinoma With Peritoneal Carcinomatosis

NCT07030283
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma (PDAC)
Interventions
Paclitaxel, NALIRIFOX
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 2, 2026 · Synced Oct 19, 2026, 9:15 PM EDT
Recruiting Phase 2 Interventional

Flat Dose vs. Weight-based IP Chemotherapy for CRS/HIPEC

NCT04779554
View directory record Official record
Conditions
Peritoneal Carcinomatosis
Interventions
Mitomycin C, flat dose 40 mg, Mitomycin C, weight-based dose 12.5 mg/m2
Drug
Lead sponsor
Prakash Pandalai
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
2
States / cities
Lexington, Kentucky • Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Oct 19, 2026, 9:15 PM EDT
Completed Phase 1 Interventional

Safety Study of ²¹²Pb-TCMC-Trastuzumab Radio Immunotherapy

NCT01384253
View directory record Official record
Conditions
Breast Neoplasms, Peritoneal Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms
Interventions
²¹²Pb-TCMC-Trastuzumab, trastuzumab
Other · Biological
Lead sponsor
Orano Med LLC
Industry
Eligibility
19 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
2
States / cities
Birmingham, Alabama • San Diego, California
Source: ClinicalTrials.gov public record
Updated Sep 30, 2016 · Synced Oct 19, 2026, 9:15 PM EDT
Completed Phase 1 Interventional

Trial of Intraperitoneal (IP) Oxaliplatin in Combination With Intravenous FOLFIRI

NCT02833753
View directory record Official record
Conditions
Colorectal Cancer, Appendix Cancer, Peritoneal Carcinomatosis
Interventions
Oxaliplatin
Drug
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years to 99 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 31, 2022 · Synced Oct 19, 2026, 9:15 PM EDT
Completed Not applicable Interventional

Daily Imaging, Target Identification, and Simulated Computed Tomography-Based Stereotactic Adaptive Radiotherapy Workflow in a Novel Ring Gantry Radiotherapy Device

NCT04008537
View directory record Official record
Conditions
Cancer of Pancreas, Cancer of Pelvis, Cancer of Abdomen, Cancer of Thorax
Interventions
Ring gantry kV-CBCT combined with linear accelerator
Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 19, 2022 · Synced Oct 19, 2026, 9:15 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Integrated Cancer Repository for Cancer Research

NCT02012699
View directory record Official record
Conditions
Pancreatic Cancer, Thyroid Cancer, Lung Cancer, Esophageal Cancer, Thymus Cancer, Colon Cancer, Rectal Cancer, Gastrointestinal Stromal Tumors, Anal Cancer, Bile Duct Cancer, Duodenal Cancer, Gallbladder Cancer, Gastric Cancer, Liver Cancer, Small Intestine Cancer, Peritoneal Surface Malignancies, Familial Adenomatous Polyposis, Lynch Syndrome, Bladder Cancer, Kidney Cancer, Penile Cancer, Prostate Cancer, Testicular Cancer, Ureter Cancer, Urethral Cancer, Hypopharyngeal Cancer, Laryngeal Cancer, Lip Cancer, Oral Cavity Cancer, Nasopharyngeal Cancer, Oropharyngeal Cancer, Paranasal Sinus Cancer, Nasal Cavity Cancer, Salivary Gland Cancer, Skin Cancer, Central Nervous System Tumor, Central Nervous System Cancer, Mesothelioma, Breast Cancer, Leukemia, Melanoma, Sarcoma, Unknown Primary Tumor, Multiple Myeloma, Ovarian Cancer, Endometrial Cancer, Vaginal Cancer, Neuroendocrine Tumors, Plasma Cell Dyscrasia, Healthy Control
Interventions
Not listed
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years to 110 Years
Enrollment
999,999 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2099
U.S. locations
42
States / cities
Greenwood Village, Colorado • Manchester, Connecticut • Daytona Beach, Florida + 34 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 19, 2026, 9:15 PM EDT
Terminated Not applicable Interventional

EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer

NCT00087191
View directory record Official record
Conditions
Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix, Fallopian Tube Cancer, Gastrointestinal Stromal Tumor, Localized Extrahepatic Bile Duct Cancer, Localized Gallbladder Cancer, Localized Gastrointestinal Carcinoid Tumor, Localized Resectable Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Metastatic Gastrointestinal Carcinoid Tumor, Ovarian Sarcoma, Ovarian Stromal Cancer, Primary Peritoneal Cavity Cancer, Recurrent Adult Primary Liver Cancer, Recurrent Adult Soft Tissue Sarcoma, Recurrent Colon Cancer, Recurrent Extrahepatic Bile Duct Cancer, Recurrent Gallbladder Cancer, Recurrent Gastric Cancer, Recurrent Gastrointestinal Carcinoid Tumor, Recurrent Non-small Cell Lung Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Ovarian Germ Cell Tumor, Recurrent Pancreatic Cancer, Recurrent Rectal Cancer, Recurrent Small Intestine Cancer, Recurrent Uterine Sarcoma, Regional Gastrointestinal Carcinoid Tumor, Small Intestine Adenocarcinoma, Small Intestine Leiomyosarcoma, Small Intestine Lymphoma, Stage 0 Non-small Cell Lung Cancer, Stage I Adult Soft Tissue Sarcoma, Stage I Colon Cancer, Stage I Gastric Cancer, Stage I Non-small Cell Lung Cancer, Stage I Ovarian Epithelial Cancer, Stage I Ovarian Germ Cell Tumor, Stage I Pancreatic Cancer, Stage I Rectal Cancer, Stage I Uterine Sarcoma, Stage II Adult Soft Tissue Sarcoma, Stage II Colon Cancer, Stage II Gastric Cancer, Stage II Non-small Cell Lung Cancer, Stage II Ovarian Epithelial Cancer, Stage II Ovarian Germ Cell Tumor, Stage II Pancreatic Cancer, Stage II Rectal Cancer, Stage II Uterine Sarcoma, Stage III Adult Soft Tissue Sarcoma, Stage III Colon Cancer, Stage III Gastric Cancer, Stage III Ovarian Epithelial Cancer, Stage III Ovarian Germ Cell Tumor, Stage III Pancreatic Cancer, Stage III Rectal Cancer, Stage III Uterine Sarcoma, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Adult Soft Tissue Sarcoma, Stage IV Colon Cancer, Stage IV Gastric Cancer, Stage IV Non-small Cell Lung Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Ovarian Germ Cell Tumor, Stage IV Pancreatic Cancer, Stage IV Rectal Cancer, Stage IV Uterine Sarcoma, Unresectable Extrahepatic Bile Duct Cancer, Unresectable Gallbladder Cancer
Interventions
EF5, motexafin lutetium, pharmacological study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 16, 2013 · Synced Oct 19, 2026, 9:15 PM EDT
Completed Not applicable Interventional Results available

MAGNET (Magnetically Controlled Capsule for Assessment of Gastric Mucosa in Symptomatic Patients)

NCT04724291
View directory record Official record
Conditions
Abdominal Pain, Gastritis, Gastric Ulcer, Gastric Cancer
Interventions
MAGNET
Device
Lead sponsor
George Washington University
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Sep 11, 2023 · Synced Oct 19, 2026, 9:15 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

A Study of Opportunistic Salpingectomy to Prevent Ovarian Cancer

NCT06312124
View directory record Official record
Conditions
Surgery
Interventions
Educational Module, Salpingectomy
Behavioral · Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
45 Years and older · Female only
Enrollment
266 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
10
States / cities
Baltimore, Maryland • Boston, Massachusetts • Basking Ridge, New Jersey + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Oct 19, 2026, 9:15 PM EDT
Completed Phase 3 Interventional Results available

Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036)

NCT03740165
View directory record Official record
Conditions
Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Neoplasms
Interventions
Pembrolizumab, Placebo for pembrolizumab, Carboplatin, Paclitaxel, Olaparib, Placebo for olaparib, Bevacizumab, Docetaxel
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older · Female only
Enrollment
1,367 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
43
States / cities
Birmingham, Alabama • Tucson, Arizona • Burbank, California + 37 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 19, 2026, 9:15 PM EDT
Not listed No phase listed Observational

Radical Trachelectomy for Women With Early Stage Cervical Cancer

NCT00813007
View directory record Official record
Conditions
Cervical Cancer
Interventions
Questionnaires
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 23, 2020 · Synced Oct 19, 2026, 9:15 PM EDT
Completed Early Phase 1 Interventional

Digital Meditation for Postoperative Pain Control After Abdominal Surgery for Cancer

NCT05346692
View directory record Official record
Conditions
Hematopoietic and Lymphoid System Neoplasm, Malignant Solid Neoplasm
Interventions
Survey Administration, Interview, Text Message-Based Navigation Intervention
Other
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 14, 2025 · Synced Oct 19, 2026, 9:15 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Ultrasound Monitoring of Abdominal Soft Tissue

NCT02722616
View directory record Official record
Conditions
Pancreatic Cancer, Liver Cancer
Interventions
Ultrasound scan of the pancreas, Ultrasound scan of the Liver, Reference ultrasound
Device · Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 100 Years
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 18, 2024 · Synced Oct 19, 2026, 9:15 PM EDT